Beneficial effects of candesartan, an angiotensin II type 1 receptor blocker, on beta-cell function and morphology in...

Area of Science:

• Endocrinology
• Pharmacology
• Metabolic Diseases

Background:

• Epidemiological studies suggest Angiotensin II type 1 receptor blockers (ARBs) reduce type 2 diabetes risk.
• Pancreatic islet dysfunction is a key feature of diabetes.

Purpose of the Study:

• To investigate if ARB treatment improves pancreatic islet abnormalities in a type 2 diabetes model.
• To elucidate the mechanisms by which ARBs may exert protective effects on islets.

Main Methods:

• db/db mice, a model for type 2 diabetes, were treated with candesartan (an ARB) for 6 weeks.
• Evaluated glucose tolerance, insulin levels, beta-cell mass, oxidative stress markers, mitochondrial volume, fibrosis, and endothelial cell loss.

Main Results:

• Candesartan improved glucose tolerance and modestly increased serum insulin in db/db mice.
• Treatment increased beta-cell mass, insulin staining, and decreased oxidative stress markers (NAD(P)H oxidase components).
• Reduced mitochondrial volume, islet fibrosis, and prevented endothelial cell loss in islets.

Conclusions:

• Candesartan treatment partially prevents glucose tolerance deterioration in a type 2 diabetes model.
• The protective effects involve mitigating beta-cell damage, oxidative stress, and improving islet microenvironment.